Low Platelet Count Linked to Thrombosis in aPL Carriers

This article originally appeared here.
Share this content:
Low Platelet Count Linked to Thrombosis in aPL Carriers
Low Platelet Count Linked to Thrombosis in aPL Carriers

MONDAY, July 10, 2017 (HealthDay News) -- For antiphospholipid antibody (aPL) carriers, low platelet count is associated with increased risk of developing thrombosis, according to a study published online June 29 in the Journal of Thrombosis and Haemostasis.

Ryo Hisada, from Hokkaido University in Sapporo, Japan, and colleagues examined the impact of platelet count in terms of predicting thrombotic events in aPL carriers in a retrospective study comprising 953 consecutive patients suspected to have autoimmune disease. Thrombotic risk was stratified by combining platelet count and antiphospholipid score (aPL-S).

The researchers observed a negative correlation between aPL-S and platelet count (r = −0.2477). Among patients who were aPL-positive, thrombosis developed more frequently in those with low platelet count versus those without (hazard ratio, 2.95). For aPL-negative patients, regardless of platelet count, there was no difference in the predictive value of thrombosis. Patients with low platelet count developed thrombosis more frequently than those without among patients with low aPL-S, (hazard ratio, 3.44); regardless of platelet count, patients with high aPL-S developed thrombosis frequently.

"aPL carriers with low platelet count are at high risk of developing thrombosis," the authors write. "In particular, 'low aPL-S carriers' may be stratified by platelet count in terms of predicting future thrombotic events."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »